Regeneron Cans 2seventy-Acquired CAR T Candidate for Lymphoma in ‘Strategic’ Move The discontinued CAR T therapy bbT369 came to Regeneron when the pharma bought all of 2seventy bio’s pipeline assets…
Lilly Dives Deeper Into Gene Therapy With up to $262M Adverum Buy The cornerstone of the deal is Ixo-vec, an intravitreal gene therapy currently in Phase III development for wet…
Biogen Grows Immunology Pipeline With Vanqua’s Anti-Inflammatory Molecule Biogen has licensed Vanqua Bio’s preclinical oral C5aR1 antagonist in a bid to pump up its immunology pipeline.Under the terms of the…
CHINA NMPA ACCEPTS NEW DRUG APPLICATION FOR HS-10365 CAPSULES FOR THE TREATMENT OF RET FUSION-POSITIVE NSCLC Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK) today announces that the New Drug…
Arcturus Plunges on ‘Mixed’ Cystic Fibrosis Data for Inhaled mRNA Drug Arcturus Therapeutics’ inhaled mRNA therapy ARCT-032 failed to show meaningful improvements in lung function in a Phase II trial…
MERS-CoV virus isolate added to the WHO BioHub System, enabling further research and pandemic preparedness Through the BioHub, countries can voluntarily share and request biological materials with epidemic or pandemic…
Biotech Markets Turn Positive but Experts Say Don’t Call It a Comeback—Yet M&A is back, the S&P XBI is rising again, a biotech pulled off an IPO and positive data…
Leadership Lab: How To Spot When Employees Are About To Walk Away Employees rarely leave companies for one reason alone. In this column, Kaye/Bassman’s Michael Pietrack shares a framework that…
Recognition highlights WuXi Biologics’ commitment to delivering exceptional value and innovative solutions to its global clients. WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today…
New findings underscore Cefiderocol’s efficacy and reliability in managing complex, multidrug-resistant bacterial infections. Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) presents…
Replimune Soars Upon FDA Resubmission for Advanced Melanoma Drug Last month, investors’ hopes were dashed as Replimune suggested alignment had not yet been reached with the FDA on RP1’s future.…
The FDA approval marks Gazyva’s first non-oncology indication, expanding Roche’s presence into autoimmune disease treatment. The anti-CD20 antibody, developed by Roche’s Genentech along with Biogen and already approved for multiple…